|Bid||0.00 x 3200|
|Ask||0.00 x 1200|
|Day's Range||5.88 - 6.16|
|52 Week Range||3.07 - 23.42|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
2021 has been a fantabulous year for stock investors, with the S&P 500 returning 25% year to date. But here’s the bad news: all good things must come to an end, and the clock’s ticking down to the end of 2021. But here’s the good news, too: 2022 might also be not too shabby a year for stocks. Most of Wall Street’s pros believe we’ll see between 8% and 12% growth going forward. That’s a sound return, and in line with the market’s long-term overall gains. What investors need to do now is optimize
Consistent with the falling temperatures outside, investors are turning a cold shoulder to synthetic biology specialist Amyris (NASDAQ: AMRS) this week. As of the close of the trading session on Thursday, shares of Amyris have plunged 47% from their closing price of $14.09 last Friday. Beginning the week on an inauspicious note, Amyris reported third-quarter 2021 earnings after the market closed on Monday.
Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris (NASDAQ: AMRS) reported disappointing third-quarter 2021 earnings results yesterday after the market closed. In addition, investors are selling shares after learning that the company is raising capital through the issuance of senior convertible notes. Although the company reported a year-over-year sales increase of 39.7%, it didn't seem to be enough to satisfy investors' appetites.